US courts to reconsider favourable Lilly ruling in NFKappaB suit
This article was originally published in Scrip
Executive Summary
A US federal appeals court will reconsider its decision in April favouring Lilly's appeal and tossing out a $65 million ruling for Ariad Pharmaceuticals in a dispute concerning a patent for treating human disease by regulating NFkappa cell signalling activity.